Hemodynamic, pharmacokinetic and clinical response to CI-930 in congestive heart failure due to ischemic or dilated cardiomyopathy

This publication has 11 references indexed in Scilit:

• Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failure
  The American Journal of Cardiology, 1986
• Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.
  Circulation, 1985
• Predictive survival models for resuscitated victims of out-of-hospital cardiac arrest with coronary heart disease.
  Circulation, 1985
• Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement.
  Circulation, 1985
• Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.
  Circulation, 1984
• Oral amrinone for the treatment of chronic congestive heart failure: Results of a multicenter randomized double-blind and placebo-controlled withdrawal study
  Journal of the American College of Cardiology, 1984
• Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure
  Journal of Medicinal Chemistry, 1984
• Inotropic drugs and their mechanisms of action
  Journal of the American College of Cardiology, 1984
• Evaluation of a New Bipyridine Inotropic Agent — Milrinone — in Patients with Severe Congestive Heart Failure
  New England Journal of Medicine, 1983
• Continuous measurement of ventilatory exchange ratio during exercise
  Journal of Applied Physiology, 1964